Appointment of Nominated Adviser and Joint Broker

Clinigen Group plc (AIM: CLIN, "Clinigen" or the “Group”), the global pharmaceutical and services company, has appointed Numis Securities Ltd as Nominated Adviser and Joint Broker with immediate effect. RBC Capital Markets will continue to act as the Group’s Joint Broker.

Contact Details

Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Tel: 44 (0) 1283 495 010

Numis Securities Limited - Nominated Adviser & Joint Broker
James Black / Freddie Barnfield / Garry Levin
Tel: 44 (0) 20 7260 1000

RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas
Tel: 44 (0)20 7653 4000

Instinctif Partners 
Adrian Duffield / Melanie Toyne Sewell / Phillip Marriage
Email: [email protected]
Tel: 44 (0)20 7457 2020

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across 100 over countries, shipping approximately 6.4 million units in the year.

For more information on Clinigen, please visit